

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 58709

Title: Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma

Reviewer's code: 03011764

Position: Editorial Board

Academic degree: MD

Professional title: Assistant Professor

Reviewer's Country/Territory: Italy

Author's Country/Territory: United States

Manuscript submission date: 2020-08-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-08-04 08:29

Reviewer performed review: 2020-08-04 09:55

Review time: 1 Hour

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

The work is very interesting because it deals with a known but still not completely resolved topic. The authors report the main evidence regarding the treatment of ICC, addressing all the fields of interest with particular reference to the use of neoadjuvant chemotherapy, widespread for periiliary tumors, but still subject to validation in intrahepatic cholangiocarcinomas (ICC). In the transplantation field, I recommend adding some works concerning the best outcome in incidental ICCs (Goss JA, Shackleton CR, Farmer DG, Arnaout WS, Seu P, Markowitz JS, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12 - year single center experience. *Ann Surg.* 1997; 225: 472-481.) and early ICC (Sapisochin G, Rodriguez de Lope C, Gastaca M, et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? *Am J Transplant* 2014; 14: 660-7. 10.1111 / ajt.12591.)